Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review
K.L. Winthrop1, Y. Tanaka2, E.B. Lee3, J. Wollenhaupt4, A. Al Enizi5, V.F. Azevedo6, J.R. Curtis7
- Department of Public Health and Preventative Medicine, Oregon Health and Science University, Portland, OR, USA. firstname.lastname@example.org
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Rheumatologie Hamburg, Struenseehaus, Hamburg, Germany.
- Rheumatology Department, Al Jahra Hospital, Al Jahra, Abu Halifa, Kuwait.
- Department of Medicine, Universidade Federal do Paraná, Curitiba, Brazil.
- Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
2022 Vol.40, N°1
PI 0162, PF 0172
Free to view
(click on article PDF icon to read the article)
PMID: 34128786 [PubMed]
Accepted : 10/03/2021
In Press: 28/05/2021
The risk of herpes zoster (HZ) and HZ-related complications is increased in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) relative to the general population; therefore, HZ vaccination is recommended in these patient groups. In this literature-based review, we summarise the available evidence on the use of HZ vaccines in patients with RA and PsA, and discuss strategies for managing breakthrough infection. Currently available data show suboptimal rates of HZ vaccination among these patients and highlight a need for strategies to improve HZ vaccination programmes in clinical practice. Further clinical studies are also required to optimise the use of HZ vaccines in patients with RA and PsA, particularly with regard to determining the impact of different immunosuppressive therapy regimens on vaccine immunogenicity and, ultimately, efficacy, as well as the impact of vaccination on disease activity and safety.